Aim: The open-label, nonrandomized, phase II APEC study enrolled 167 patients with RAS wildtype (wt) metastatic colorectal cancer (mCRC) to investigate the safety and efficacy of firstline, every-2-weeks cetuximab plus investigator's choice of FOLFIRI or FOLFOX in this patient population.
doublet chemotherapy regimens available for the treatment of mCRC: FOLFIRI (infusional fluorouracil /leucovorin/irinotecan) or FOLFOX (infusional 5-FU/oxaliplatin/folinic acid [leucovorin]). 2, 3 Currently, median survival in trials for patients with RAS wt mCRC receiving systemic therapy is ≥30 months, 2,3 although certain patient subpopulations have worse prognoses. 4, 5 The location of the primary tumor within the colorectal tract (right vs left) has significant prognostic value for patient survival. Indeed, patients with right-sided RAS wt tumors have a worse prognosis-that is, much poorer survival outcomes than patients with left-sided tumors, regardless of the treatment received. In addition, right-sidedness appears to have predictive value, as patients with right-sided RAS wt mCRC have been shown to derive less benefit from treatment with cetuximab than patients with left-sided RAS wt mCRC. By comparison, patients with left-sided RAS wt tumors appear to fare better if treated with anti-EGFR therapy plus chemotherapy versus bevacizumab plus chemotherapy. 3, 6 The open-label, nonrandomized, multicenter, phase II APEC trial demonstrated that first-line cetuximab administered once every 2 weeks in combination with investigator's choice of either FOLFOX or FOLFIRI yielded good response and survival outcomes in an Asian patient population with RAS wt mCRC, with no new or unexpected safety findings. 7 Furthermore, the APEC trial found no evidence for differences in efficacy between FOLFIRI and FOLFOX chemotherapy when combined with cetuximab in patients with RAS wt mCRC. 7 In this subgroup analysis, we present the efficacy outcomes of the APEC trial by chemotherapy backbone for each tumor location.
METHODS
Detailed design and methodology for the nonrandomized, phase II APEC study (NCT00778830) were previously described. 7 The trial was conducted in accordance with the Declaration of Helsinki. The protocol was approved by the ethics committees of all participating centers. All patients gave written informed consent before trial entry.
Briefly, 289 patients with previously untreated KRAS exon 2 (codon 12/13) wt mCRC and an Eastern Cooperative Oncology Group performance status of 0 or 1 were enrolled and assigned to a treatment by participating investigators (cetuximab plus FOLFIRI, n = 101; cetuximab plus FOLFOX, n = 188). Of these, 167 patients had RAS wt disease according to extended RAS analysis (cetuximab plus FOLFIRI, n = 57; cetuximab plus FOLFOX, n = 110). In this population, 159 patients 10 there is no evidence that the safety profile differs meaningfully between right-and left-sided mCRC.
DISCUSSION
Here we present the tumor-location subgroup analysis of the phase II APEC study population of patients with RAS wt mCRC. This is the first study to provide tumor-location analyses for subgroups treated with the combination of every-2-weeks cetuximab plus FOLFIRI and cetuximab plus FOLFOX in parallel, and this thus serves as a hypothesis-generating landmark study. Because the APEC study was Resection rate, n (%) 1 (2. and TAILOR (44% with cetuximab plus FOLFOX) studies. 3, 10 Therefore, this study provides further evidence that this may potentially be a preferred combination therapy for right-sided mCRC when cytoreduction is a key treatment goal. Thus, first-line cetuximab plus FOL-FOX or FOLFIRI can be considered for right-sided RAS wt mCRC when the patient requires rapid tumor shrinkage to improve symptoms or facilitate resection. Finally, in agreement with previous observations, both cetuximab plus FOLFIRI and cetuximab plus FOLFOX yielded high response rates in patients with left-sided RAS wt mCRC. 3 Although the higher rate of BRAF mutations in cetuximab plus FOLFOX-treated patients with right-sided disease may partially explain dissimilarities in PFS and OS between the FOLFOX and FOLFIRI cohorts, another possible explanation for the observed trends may be that the synergy between cetuximab and irinotecan observed in preclinical models 11, 12 is sufficient to overcome some of the molecular mechanisms that limit the benefits of antitumor therapy in rightsided mCRC. This was reinforced clinically in the BOND study, in which patients who were resistant to irinotecan had improved ORR and PFS when treated with cetuximab and irinotecan compared to cetuximab alone. 13 Further investigation of these findings is required. In summary, these results serve to generate interesting hypotheses regarding the choice of chemotherapy backbone with first-line cetuximab for the treatment of patients with right-sided mCRC.
